![]() Primaquine, the most commonly used anti-malaria drug, can trigger hemolytic anemia in people with G6PDH deficiency. Glucose-6-phosphate dehydrogenase (G6PDH) deficiency is an inherited metabolic disorder that affects more than 400 million people worldwide and for which there is a strong need for improvements in point-of-care diagnostic devices. We showed how we can set flow rate conditions for laminar co-flow of two liquids and monitor an enzymatic reaction in different flow conditions. ![]() To provide an example of a new functional element developed for CAPSYS, we havea implemented a programmable hydraulic resistor in which an array of “electrogates” routes an incoming liquid through a set of resistors to modulate flow rates in microfluidic chips post-fabrication. reaction conditions can be optimized using specific microfluidic functional elements.small quantities of reagents and samples can be employed, and.the flow of liquids is typically laminar and predictable,.In this project, we exploit the physics of liquids at the microscale, where ![]() CAPSYSĬAPSYS aims at developing simple-to-use and high-performance microfluidic capillary systems for point-of-care testing. Using smartphones and custom-made peripherals, we recently demonstrated the inclusion of anti-counterfeiting security codes, called “crypto anchors”, in microfluidic devices, a new concept for stop-and-go liquid flow control (“electrogates”), and real-time flow monitoring with sub-nanoliter/second precision.įurthermore, we believe this technology can generate high-value, critical data for many scenarios involving Watson Health and IBM’s expertise with IT and security platforms. Our vision is to enable quantitative diagnostics and to connect microfluidic chips to smartphones for fast and convenient analysis of numerous samples. We have also recently started to integrate solid-state sensors into microfluidics for wearable applications in collaboration with the IBM Watson Research Center in New York. We have pioneered numerous concepts involving capillary phenomena to develop a library of microfluidic functions for implementing biological assays in microfluidics. We also have partners from academic and governmental research institutions within collaborative research projects. Our partners are usually from the in vitro diagnostics industry and the semiconductor and MEMS sectors. We typically partner with companies and institutions, helping them use our technologies via joint development projects and licensing programs. Originally supported by the Swiss Commission for Technology and Innovation (CTI) in partnership with the University Hospital of Basel, this research has now branched out into various directions. We are developing technologies to implement biological assays on microfluidics for point-of-care diagnostic applications. ![]() ![]() Our current challenges deal with the rapid and precise detection of analytes for point-of-care diagnostics. Over the years, we have gradually shifted from research on self-assembly, soft lithography and microtechnology to issues in biology and medicine where critical technology gaps exist. Therefore, new bioanalytical tools are critically needed to push the frontiers of knowledge in life sciences and to improve healthcare. In addition, precise analysis of biological samples is vital for diagnostics and managing patients. Much of the knowledge we have in biology and medicine is derived from the ability to detect analytes from complex biological samples. Our goal is to solve important medical problems while generating massive amounts of high-value data. In the precision diagnostics project, we are creating enabling technologies for healthcare and life sciences using multidisciplinary research and a problem-oriented agenda. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |